NMRAL1: A Potential Drug Target and Biomarker for Cancer (G57407)

Target Name: NMRAL1

NCBI ID: G57407

NMRAL1

NMRAL1: A Potential Drug Target and Biomarker for Cancer

NMRAL1 (NmrA-like family domain-containing protein 1) is a protein that has been identified as a potential drug target or biomarker. It is a member of the NmrA-like family, which is a conserved group of proteins that play important roles in various cellular processes. The NmrA-like family is characterized by the presence of a specific domain, known as the NmrA-like domain, which is responsible for the protein's unique structure and function.

The NmrA-like domain is a transmembrane domain that is characterized by the presence of a long coiled region and several distinct conserved amino acid residues. It is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. In addition, the NmrA-like domain is also involved in the regulation of protein-protein interactions and in the modulation of cellular signaling pathways.

NMRAL1, as a potential drug target, has been identified for its role in the regulation of cell proliferation and the development of cancer. Studies have shown that high levels of NMRAL1 are associated with the development of various types of cancer, including breast, ovarian, and prostate cancer. In addition, the NmrA-like domain is also involved in the regulation of cell apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. The NmrA-like domain has been shown to play a role in the regulation of cell apoptosis in various cellular contexts, including the regulation of cell death in response to chemotherapy drugs.

In addition to its potential role as a drug target, NMRAL1 has also been identified as a potential biomarker for the diagnosis and prognosis of various types of cancer. The NmrA-like domain is highly conserved across various species, which suggests that it is a reliable and robust marker for cancer diagnosis and prognosis. Studies have shown that the expression of NMRAL1 is significantly associated with the poor prognosis of various types of cancer, including breast, ovarian, and prostate cancer. In addition, the NmrA-like domain has also been shown to play a role in the regulation of cancer cell migration and invasion, which may have implications for the development of new cancer therapies.

In conclusion, NMRAL1 is a protein that has been identified as a potential drug target and biomarker for the development of cancer. The NmrA-like domain is a transmembrane domain that is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. High levels of NMRAL1 are associated with the development of various types of cancer, and the NmrA-like domain has also been shown to play a role in the regulation of cell apoptosis and cancer cell migration and invasion. Further research is needed to fully understand the role of NMRAL1 as a drug target and biomarker for cancer.

Protein Name: NmrA Like Redox Sensor 1

Functions: Redox sensor protein. Undergoes restructuring and subcellular redistribution in response to changes in intracellular NADPH/NADP(+) levels. At low NADPH concentrations the protein is found mainly as a monomer, and binds argininosuccinate synthase (ASS1), the enzyme involved in nitric oxide synthesis. Association with ASS1 impairs its activity and reduces the production of nitric oxide, which subsecuently prevents apoptosis. Under normal NADPH concentrations, the protein is found as a dimer and hides the binding site for ASS1. The homodimer binds one molecule of NADPH. Has higher affinity for NADPH than for NADP(+). Binding to NADPH is necessary to form a stable dimer

The "NMRAL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NMRAL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets